Hims & Hers: Investors Eligible to Lead Class Action Lawsuit
Purchasers of Hims & Hers Health securities between August 4, 2025, and July 29, 2026, who incurred substantial losses, have until November 2, 2026, to seek appointment as lead plaintiff in a class action lawsuit.
San Diego, CA – Robbins Geller Rudman & Dowd LLP has announced that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, inclusive, may be eligible to serve as lead plaintiff in a class action lawsuit. The deadline for investors to seek this role is Monday, November 2, 2026.
The lawsuit, Velanki v. Hims & Hers Health, Inc., alleges violations of the Securities Exchange Act of 1934 by Hims & Hers and certain of its executives. The core allegations state that the company shared consumer health information with third-party advertising platforms. Furthermore, the complaint claims Hims & Hers charged consumers for prescriptions almost immediately after form submission, contrary to representations that users would consult a medical provider to find suitable treatment.
On July 29, 2026, the Federal Trade Commission (FTC) reportedly filed a lawsuit against Hims & Hers. The FTC complaint alleges that the telehealth provider shared sensitive health data with advertising platforms such as Meta Platforms and Snap Inc., despite privacy assurances. The suit also accuses the company of deceptive billing and cancellation practices.
Following the FTC's announcement, Hims & Hers shares declined nearly 15%. The class action lawsuit aims to recover damages for investors who suffered losses due to these alleged misrepresentations and omissions concerning the company's business practices and regulatory compliance. Interested investors should contact Robbins Geller Rudman & Dowd LLP to learn more about their rights and the lead plaintiff selection process.